Description

Remo-V Tablet is a combination medicine containing Vildagliptin and Remogliflozin. Vildagliptin belongs to a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors, whereas Remogliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This medication is primarily used to treat type 2 diabetes mellitus. It helps control blood sugar levels by increasing insulin secretion and reducing glucose production in the liver, as well as by promoting the excretion of excess glucose in the urine. Remo-V Tablet aids in improving glycemic control and effectively managing diabetes symptoms. It is typically prescribed along with a proper diet and exercise program. However, it is important to note that this medication should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis.

Additional information